MK-4618 + metoprolol

MK-4618 is the code name for **vibegron**, a selective β3-adrenergic receptor agonist developed for the treatment of overactive bladder (OAB). Metoprolol is a selective beta-1 adrenergic receptor blocker (beta-blocker) used primarily to manage hypertension, angina, and heart failure. This combination drug consists of vibegron (MK-4618) and metoprolol, representing a dual therapy utilizing both a β3-adrenergic agonist for OAB and a beta-blocker for cardiovascular indications. There are no known approved products or clinical trials investigating the combination of MK-4618 (vibegron) with metoprolol specifically. Vibegron has been studied, often in combination with antimuscarinics such as tolterodine, but not with beta-blockers. Therefore, this combination is not an established or approved therapeutic regimen, and information on its use, safety, or efficacy as a combination is not available in the literature[2][4][6].

Other names

vibegron + metoprolol